Also trades as: TCBPW (NASDAQ) · $vol 0M
TCBP NASDAQ
TC Biopharm (Holdings) Plc
1W: +63.3%
1M: -69.8%
3M: -93.8%
1Y: -99.8%
3Y: -100.0%
$0.50
Last traded 2025-04-17 — delisted
Overview
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Smart Money Score
No convergence signal
Key Statistics
Market Cap$0.3M
52W Range0.08-523.2
Volume5,896,474
Avg Volume377,721
Beta0.01
Dividend—
Analyst Ratings
Company Info
CEOBryan Leland Kobel
Employees41
SectorHealthcare
IndustryBiotechnology
IPO Date2022-02-11
Websitetcbiopharm.com
Maxim 1
Motherwell ML1 4WR
GB
Motherwell ML1 4WR
GB
44 14 1433 7557
About TC Biopharm (Holdings) Plc
Operating as a clinical-stage biopharmaceutical entity, TC Biopharm (Holdings) Plc is dedicated to pioneering immunotherapy solutions, leveraging its proprietary allogeneic gamma delta T cell platform. Its developmental portfolio includes OmnImmune, an unmodified cellular therapy aimed at acute myeloid leukemia, and ImmuniStim, another unmodified cellular therapy designed to combat COVID-19. The company was established in 2013 and is headquartered in Motherwell, United Kingdom.
Latest News
No recent news
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Randall Diana Elizab | P-Purchase | 70,000 | — | 2022-11-30 |
| Randall Kenneth Edwa | P-Purchase | 70,000 | — | 2022-11-30 |
| Randall Mark Edward | P-Purchase | 70,000 | — | 2022-11-30 |
| Renaissance Capital | P-Purchase | 70,000 | — | 2022-11-30 |
| Randall Diana Elizab | 0 | — | 2022-02-10 |